. "IgD typ mnoho\u010Detn\u00E9ho myelomu (MM) p\u0159edstavuje pom\u011Brn\u011B vz\u00E1cnou formu tohoto st\u00E1le nevyl\u00E9\u010Diteln\u00E9ho onemocn\u011Bn\u00ED, postihuje p\u0159ibli\u017En\u011B 2 % v\u0161ech nemocn\u00FDch s MM. Provedli jsme retrospektivn\u00ED anal\u00FDzu v\u00FDsledk\u016F l\u00E9\u010Dby 20 nemocn\u00FDch ze 4 center spolupracuj\u00EDc\u00EDch v r\u00E1mci \u010Cesk\u00E9 myelomov\u00E9 skupiny. Z na\u0161ich v\u00FDsledk\u016F jednozna\u010Dn\u011B vypl\u00FDv\u00E1 nutnost l\u00E9\u010Dit nemocn\u00E9 s IgD MM do 65 let v\u011Bku vysokod\u00E1vkovou l\u00E9\u010Dbou, kter\u00E1 umo\u017E\u0148uje dosa\u017Een\u00ED srovnateln\u00FDch v\u00FDsledk\u016F s ostatn\u00EDmi typy mnoho\u010Detn\u00E9mu myelomu. Dal\u0161\u00ED zlep\u0161en\u00ED l\u00E9\u010Debn\u00FDch v\u00FDsledk\u016F by mohlo nastat v souvislosti se st\u00E1le \u010Dast\u011Bj\u0161\u00EDm pou\u017E\u00EDv\u00E1n\u00EDm nov\u00FDch l\u00E9k\u016F v l\u00E9\u010Db\u011B MM." . "[376DC2AACF07]" . "15 (36)" . . . "RIV/00216208:11150/07:00004049!RIV08-MSM-11150___" . "RIV/00216208:11150/07:00004049" . "Maisnar, Vladim\u00EDr" . "1210-7921" . . . "IgD mnoho\u010Detn\u00FD myelom - retrospektivn\u00ED anal\u00FDza l\u00E9\u010Debn\u00FDch v\u00FDsledk\u016F 47 center \u010Cesk\u00E9 republiky za posledn\u00EDch 7 let"@cs . "CZ - \u010Cesk\u00E1 republika" . "IgD mnoho\u010Detn\u00FD myelom - retrospektivn\u00ED anal\u00FDza l\u00E9\u010Debn\u00FDch v\u00FDsledk\u016F 47 center \u010Cesk\u00E9 republiky za posledn\u00EDch 7 let"@cs . . . "IgD multiple myeloma belongs to relatively rare types of plasmacytomas and affects less than 2% of all MM-patients. Survival of patients with IgD MM is generally believed to be shorter than that of patients with other types of M-protein. We carried out a retrospective analysis of 20 myeloma patients treated by 4 Czech hemato-oncological centers in last seven years. It is necessary to consider high-dose therapy with following APBSCT when treating patients with IgD MM under 65 years because it is possible to reach similar results compared to patients with other MM types."@en . . . "Klinick\u00E1 biochemie a metabolismus" . . "2"^^ . "2" . "Mal\u00FD, Jaroslav" . "425425" . "IgD multiple myeloma - retrospective analysis of therapeutic results of 4 centres of the Czech Republic over the last 7 years"@en . . . "IgD multiple myeloma - retrospective analysis of therapeutic results of 4 centres of the Czech Republic over the last 7 years"@en . . "70;73" . . "9"^^ . "multiple; myeloma; retrospective; analysis; therapeutic; results; centres; Czech; Republic; years"@en . "IgD mnoho\u010Detn\u00FD myelom - retrospektivn\u00ED anal\u00FDza l\u00E9\u010Debn\u00FDch v\u00FDsledk\u016F 47 center \u010Cesk\u00E9 republiky za posledn\u00EDch 7 let" . "4"^^ . "S" . . . . "IgD mnoho\u010Detn\u00FD myelom - retrospektivn\u00ED anal\u00FDza l\u00E9\u010Debn\u00FDch v\u00FDsledk\u016F 47 center \u010Cesk\u00E9 republiky za posledn\u00EDch 7 let" . . . . "11150" . "IgD typ mnoho\u010Detn\u00E9ho myelomu (MM) p\u0159edstavuje pom\u011Brn\u011B vz\u00E1cnou formu tohoto st\u00E1le nevyl\u00E9\u010Diteln\u00E9ho onemocn\u011Bn\u00ED, postihuje p\u0159ibli\u017En\u011B 2 % v\u0161ech nemocn\u00FDch s MM. Provedli jsme retrospektivn\u00ED anal\u00FDzu v\u00FDsledk\u016F l\u00E9\u010Dby 20 nemocn\u00FDch ze 4 center spolupracuj\u00EDc\u00EDch v r\u00E1mci \u010Cesk\u00E9 myelomov\u00E9 skupiny. Z na\u0161ich v\u00FDsledk\u016F jednozna\u010Dn\u011B vypl\u00FDv\u00E1 nutnost l\u00E9\u010Dit nemocn\u00E9 s IgD MM do 65 let v\u011Bku vysokod\u00E1vkovou l\u00E9\u010Dbou, kter\u00E1 umo\u017E\u0148uje dosa\u017Een\u00ED srovnateln\u00FDch v\u00FDsledk\u016F s ostatn\u00EDmi typy mnoho\u010Detn\u00E9mu myelomu. Dal\u0161\u00ED zlep\u0161en\u00ED l\u00E9\u010Debn\u00FDch v\u00FDsledk\u016F by mohlo nastat v souvislosti se st\u00E1le \u010Dast\u011Bj\u0161\u00EDm pou\u017E\u00EDv\u00E1n\u00EDm nov\u00FDch l\u00E9k\u016F v l\u00E9\u010Db\u011B MM."@cs . . .